Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer

BMC Gastroenterol. 2022 Apr 16;22(1):190. doi: 10.1186/s12876-022-02257-2.

Abstract

Colon cancer (CC) is a disease with high incidence and mortality rate. The interaction between epithelial-mesenchymal transition (EMT) and immune status has important clinical significance. We aim to identify EMT-immune-related prognostic biomarkers in colon cancer. The GEO2R and GEPIA 2.0 were utilized to calculate the differential expression genes between CC and normal mucosa. Immport, InnateDB and EMTome databases were used to define EMT-immune-related genes. We conducted batch prognostic analysis by TCGA data. The expression patterns were verified by multiple datasets and lab experiments. GEPIA 2.0 and TIMER 2.0 were utilized to analyze the correlation of the hub genes with EMT markers and immune infiltration. GeneMANIA, STRING, and Metascape were used for co-expression and pathway enrichment analysis. Finally, we established a signature by the method of multivariate Cox regression analysis. CDKN2A, CMTM8 and ILK were filtered out as prognostic genes. CDKN2A and CMTM8 were up-regulated, while ILK was down-regulated in CC. CDKN2A was positively correlated with infiltration of macrophages, Th2 cells, Treg cells, and negatively correlated with NK cells. CMTM8 was negatively correlated with CD8+ T cells, dendritic cells, and NK cells. ILK was positively correlated with CD8+ T cells and dendritic cells. Moreover, CDKN2A, CMTM8 and ILK were significantly correlated with EMT markers. The three genes could participate in the TGF-β pathway. The prognosis model established by the three hub genes was an independent prognosis factor, which can better predict the prognosis. CDKN2A, CMTM8 and ILK are promising prognostic biomarkers and may be potential therapeutic targets in colon cancer.

Keywords: Bioinformatics analysis; Biomarker; Colon cancer; Epithelial-mesenchymal transition; Immune; Prognosis.

MeSH terms

  • Biomarkers, Tumor / immunology
  • Chemokines* / genetics
  • Chemokines* / immunology
  • Colonic Neoplasms*
  • Cyclin-Dependent Kinase Inhibitor p16* / immunology
  • Epithelial-Mesenchymal Transition*
  • Humans
  • MARVEL Domain-Containing Proteins* / immunology
  • Prognosis
  • Protein Serine-Threonine Kinases* / immunology

Substances

  • Biomarkers, Tumor
  • CDKN2A protein, human
  • CMTM8 protein, human
  • Chemokines
  • Cyclin-Dependent Kinase Inhibitor p16
  • MARVEL Domain-Containing Proteins
  • integrin-linked kinase
  • Protein Serine-Threonine Kinases